Literature DB >> 12741957

A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport.

Hideyuki Mitomo1, Ryo Kato, Akiko Ito, Shiho Kasamatsu, Yoji Ikegami, Isao Kii, Akira Kudo, Eiry Kobatake, Yasuhiro Sumino, Toshihisa Ishikawa.   

Abstract

Overexpression of the ATP-binding cassette transporter ABCG2 reportedly causes multidrug resistance, whereas altered drug-resistance profiles and substrate specificity are implicated for certain variant forms of ABCG2. At least three variant forms of ABCG2 have been hitherto documented on the basis of their amino acid moieties (i.e., arginine, glycine and threonine) at position 482. In the present study we have generated those ABCG2 variants by site-directed mutagenesis and expressed them in HEK-293 cells. Exogenous expression of the Arg(482), Gly(482), and Thr(482) variant forms of ABCG2 conferred HEK-293 cell resistance toward mitoxantrone 15-, 47- and 54-fold, respectively, as compared with mock-transfected HEK-293 cells. The transport activity of those variants was examined by using plasma-membrane vesicles prepared from ABCG2-overexpressing HEK-293 cells. [Arg(482)]ABCG2 transports [(3)H]methotrexate in an ATP-dependent manner; however, no transport activity was observed with the other variants (Gly(482) and Thr(482)). Transport of methotrexate by [Arg(482)]ABCG2 was significantly inhibited by mitoxantrone, doxorubicin and rhodamine 123, but not by S -octylglutathione. Furthermore, ABCG2 was found to exist in the plasma membrane as a homodimer bound via cysteinyl disulphide bond(s). Treatment with mercaptoethanol decreased its apparent molecular mass from 140 to 70 kDa. Nevertheless, ATP-dependent transport of methotrexate by [Arg(482)]ABCG2 was little affected by such mercaptoethanol treatment. It is concluded that Arg(482) is a critical amino acid moiety in the substrate specificity and transport of ABCG2 for certain drugs, such as methotrexate.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12741957      PMCID: PMC1223553          DOI: 10.1042/BJ20030150

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  36 in total

Review 1.  The human ATP-binding cassette (ABC) transporter superfamily.

Authors:  M Dean; A Rzhetsky; R Allikmets
Journal:  Genome Res       Date:  2001-07       Impact factor: 9.043

Review 2.  Multidrug resistance: molecular mechanisms and clinical relevance.

Authors:  V Ling
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

3.  Does ABCG2 need a heterodimer partner? Expression and functional evaluation of ABCG2 (Arg 482)*.

Authors:  Megumi Yoshikawa; Shiho Kasamatsu; Masa Yasunaga; Guizhi Wang; Yoji Ikegami; Hisahiro Yoshida; Shigeki Tarui; Hikaru Yabuuchi; Toshihisa Ishikawa
Journal:  Drug Metab Pharmacokinet       Date:  2002       Impact factor: 3.614

4.  Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization.

Authors:  Kumie Kage; Satomi Tsukahara; Tomomi Sugiyama; Sakiyo Asada; Etsuko Ishikawa; Takashi Tsuruo; Yoshikazu Sugimoto
Journal:  Int J Cancer       Date:  2002-02-10       Impact factor: 7.396

5.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

Authors:  M Maliepaard; G L Scheffer; I F Faneyte; M A van Gastelen; A C Pijnenborg; A H Schinkel; M J van De Vijver; R J Scheper; J H Schellens
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

6.  Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia.

Authors:  Dorina M van der Kolk; Edo Vellenga; George L Scheffer; Michael Müller; Susan E Bates; Rik J Scheper; Elisabeth G E de Vries
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

7.  Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.

Authors:  Csilla Ozvegy; András Váradi; Balázs Sarkadi
Journal:  J Biol Chem       Date:  2002-10-08       Impact factor: 5.157

8.  Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.

Authors:  M Brangi; T Litman; M Ciotti; K Nishiyama; G Kohlhagen; C Takimoto; R Robey; Y Pommier; T Fojo; S E Bates
Journal:  Cancer Res       Date:  1999-12-01       Impact factor: 12.701

9.  Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance.

Authors:  Erin L Volk; Kate M Farley; Yan Wu; Fei Li; Robert W Robey; Erasmus Schneider
Journal:  Cancer Res       Date:  2002-09-01       Impact factor: 12.701

10.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.

Authors:  R Allikmets; L M Schriml; A Hutchinson; V Romano-Spica; M Dean
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

View more
  31 in total

Review 1.  Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design.

Authors:  Toshihisa Ishikawa; Ai Tamura; Hikaru Saito; Kanako Wakabayashi; Hiroshi Nakagawa
Journal:  Naturwissenschaften       Date:  2005-10

Review 2.  ATP-binding cassette, subfamily G (ABCG family).

Authors:  Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Pflugers Arch       Date:  2006-09-16       Impact factor: 3.657

3.  Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level.

Authors:  Kyoung-Ah Kim; Hyun-Jin Joo; Ji-Young Park
Journal:  Eur J Clin Pharmacol       Date:  2010-10-23       Impact factor: 2.953

Review 4.  Transporters in the intestine limiting drug and toxin absorption.

Authors:  R P J Oude Elferink; R de Waart
Journal:  J Physiol Biochem       Date:  2007-03       Impact factor: 4.158

5.  The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding.

Authors:  Karin F K Ejendal; Ndeye Khady Diop; Linda C Schweiger; Christine A Hrycyna
Journal:  Protein Sci       Date:  2006-07       Impact factor: 6.725

6.  Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo.

Authors:  Kamlesh Sodani; Atish Patel; Nagaraju Anreddy; Satyakam Singh; Dong-Hua Yang; Rishil J Kathawala; Priyank Kumar; Tanaji T Talele; Zhe-Sheng Chen
Journal:  Biochem Pharmacol       Date:  2014-02-22       Impact factor: 5.858

Review 7.  ABCG transporters: structure, substrate specificities and physiological roles : a brief overview.

Authors:  Saroj Velamakanni; Shen L Wei; Tavan Janvilisri; Hendrik W van Veen
Journal:  J Bioenerg Biomembr       Date:  2007-12       Impact factor: 2.945

8.  Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations.

Authors:  Tomoka Furukawa; Kanako Wakabayashi; Ai Tamura; Hiroshi Nakagawa; Yoshihiro Morishima; Yoichi Osawa; Toshihisa Ishikawa
Journal:  Pharm Res       Date:  2008-10-29       Impact factor: 4.200

9.  Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.

Authors:  Chun-ling Dai; Amit K Tiwari; Chung-Pu Wu; Xiao-Dong Su; Si-Rong Wang; Dong-geng Liu; Charles R Ashby; Yan Huang; Robert W Robey; Yong-ju Liang; Li-ming Chen; Cheng-Jun Shi; Suresh V Ambudkar; Zhe-Sheng Chen; Li-wu Fu
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

10.  Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters.

Authors:  J Jacob Strouse; Irena Ivnitski-Steele; Anna Waller; Susan M Young; Dominique Perez; Annette M Evangelisti; Oleg Ursu; Cristian G Bologa; Mark B Carter; Virginia M Salas; George Tegos; Richard S Larson; Tudor I Oprea; Bruce S Edwards; Larry A Sklar
Journal:  Anal Biochem       Date:  2013-03-05       Impact factor: 3.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.